Eastern Europe Cancer Therapeutics Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The cancer therapeutics market size is expected to reach US$ 21,658.26 million by 2031 from US$ 10,144.33 million in 2024. The market is estimated to record a CAGR of 11.58% from 2025 to 2031.

Executive Summary and Eastern Europe Cancer Therapeutics Market Analysis:

The cancer therapeutics market in Eastern Europe is experiencing significant growth driven by several key factors, including growing burden of breast and lung cancer and surging investments in oncology research. For instance, the Polish National Cancer Registry reported ~171,558 new cancer cases and 93,652 cancer-related deaths in 2021. According to the Spanish Network of Cancer Registries, Poland reported ~8,805 breast cancer-related deaths in 2021. Thus, the Polish cancer therapeutics market continues to expand with the rising need for more advanced and effective treatments.

Eastern Europe Cancer Therapeutics Market Segmentation Analysis:

Key segments that contributed to the derivation of the cancer therapeutics market analysis are therapy type, indication, and distribution channel.

By therapy type, the cancer therapeutics market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The chemotherapy segment dominated the market in 2024. In terms of indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment held the largest share of the market in 2024 By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the market in 2024.

Eastern Europe Cancer Therapeutics Market Outlook

The cancer therapeutics market in Eastern Europe is experiencing significant growth driven by growing burden of breast and lung cancer and surging investments in oncology research contributes significantly to overall market growth. The Eastern Eastern Europe cancer therapeutics market is segmented into Poland, Ukraine, Romania, and Greece. Governments in Eastern Europe, alongside EU funding programs, are investing in healthcare improvements and cancer research. Initiatives to support innovative cancer treatments, such as the EU's Horizon Europe program, provide financial backing for new therapies, helping to bring cutting-edge treatments to the region.

Eastern Europe Cancer Therapeutics Market Country Insights

Based on region, the Eastern Europe cancer therapeutics market is further segmented into Poland, Ukraine, Romania, and Greece. The Poland held the largest share in 2024.

The cancer therapeutics market in Poland is experiencing rapid growth, driven by the rising incidence of cancer and advancements in treatment technologies. Cancer is one of the primary causes of death in the country; the Polish National Cancer Registry reported ~171,558 new cancer cases and 93,652 cancer-related deaths in 2021. According to the Spanish Network of Cancer Registries, Poland reported ~8,805 breast cancer-related deaths in 2021. Thus, the Polish cancer therapeutics market continues to expand with the rising need for more advanced and effective treatments.

The government is implementing crucial initiatives to combat the socioeconomic challenge posed by cancer. The Polish Ministry of Health has launched the National Cancer Control Program (NCCP) with an aim to reduce cancer morbidity and mortality through early detection, prevention, and improved treatment quality. Additionally, the National Cancer Strategy 2020–2030, effective from April 2020, replaces the previous National Programme for Cancer Diseases Control (2016–2024) and offers a comprehensive approach to cancer care in the country, aligning with Europe's Beating Cancer Plan. The main objectives of this strategy include enhancing five-year survival rates after cancer treatment, improving early cancer detection, and increasing the quality of life for patients during and after treatment.

Eastern Europe Cancer Therapeutics Market Company Profiles

Astellas Pharma Inc; Eli Lilly and Co; Novartis AG; Merck KGaA.; Johnson & Johnson; AstraZeneca; Pfizer Inc; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd; and AbbVie are among the key players operating in the market. These companies are engaged in collaborative drug development to bring novel therapeutics for cancer in the market, aiming to stay ahead on competitive edge.

Eastern Europe Cancer Therapeutics Market Research Methodology:

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

Company websites, annual reports, financial statements, broker analyses, and investor presentations Industry trade journals and other relevant publications Government documents, statistical databases, and market reports News articles, press releases, and webcasts specific to companies operating in the marketNote:All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

Business Market Insights conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:

Refine findings from secondary research Enhance the expertise and market understanding of the analysis team Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:

Industry stakeholders:

Vice Presidents, business development managers, market intelligence managers, and national sales managers External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise Key Sources Referred:

World Health Organization (WHO) Macmillan Cancer Support Global Cancer Observatory Eurostat Spanish Network of Cancer Registries Danish Cancer Society Finnish Cancer Registry European Cancer Information System (ECIS)